Trobix Bio is a pioneering biotech company based in Israel, specializing in the field of human microbiome. With our innovative TBX™ technology platform, which combines CRISPR, phage, and synthetic biology, we aim to re-program specific activities in targeted microbiome bacteria. Our focus is on developing orally administered precision oncology therapeutics.

Our preclinical products, TBX201 and TBX301, are currently in development and have the potential to significantly reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. By doing so, our products may enable physicians to complete more oncology treatments and enhance the quality of life for cancer patients. What sets us apart is our strong scientific foundation, supported by multiple patent families and high-impact publications.

We leverage phage engineering and CRISPR technologies to create innovative microbiome therapeutics. Our dedicated interdisciplinary team of highly skilled professionals ensures that we stay at the forefront of this cutting-edge field. Contact us at 45 Ha’Melacha Street, Netanya, Israel, or via email at info@trobix.

bio. Visit our website for more information. Together, let's make a difference in the world of precision oncology therapeutics.

© Trobix Bio. All Rights Reserved. Terms of Use and Privacy Policy apply.

Website designed by Volle'